Part I Overview Information


Department of Health and Human Services

Issuing Organization
National Cancer Institute (NCI), (http://www.nci.nih.gov/)

Participating Organizations
National Institutes of Health (NIH), (http://www.nih.gov)

Components of Participating Organizations
National Cancer Institute (NCI), (http://www.nci.nih.gov/)

Title: NCI Competitive Supplements for Pilot Projects for Community Networks Program to Reduce Cancer Health Disparities (U01)

Announcement Type
This RFA is affiliated with RFA-CA-05-012, which was released on April 26, 2004.

Update: The following update relating to this announcement has been issued:

Request For Applications (RFA) Number: RFA-CA-06-504 

Catalog of Federal Domestic Assistance Number(s)
93.393, 93.394, 93.399

Key Dates 
Release Date:  March 2, 2006
Letters of Intent Receipt Date(s): March 24, 2006.
Application Receipt Dates(s):  April 24, 2006
Peer Review Date(s): July 2006
Council Review Date(s): September 2006
Earliest Anticipated Start Date: September 2006
Additional Information To Be Available Date (URL Activation Date):  Not applicable.
Expiration Date: April 25, 2006.

Due Dates for E.O. 12372
Not Applicable

Additional Overview Content

Executive Summary

Table of Contents


Part I Overview Information

Part II Full Text of Announcement

Section I. Funding Opportunity Description
  1. Research Objectives

Section II. Award Information
  1. Mechanism(s) of Support
  2. Funds Available

Section III. Eligibility Information
  1. Eligible Applicants
    A. Eligible Institutions
    B. Eligible Individuals
  2. Cost Sharing or Matching
  3. Other - Special Eligibility Criteria

Section IV. Application and Submission Information
  1. Address to Request Application Information
  2. Content and Form of Application Submission
  3. Submission Dates and Times
    A. Receipt and Review and Anticipated Start Dates
      1. Letter of Intent
    B. Sending an Application to the NIH
    C. Application Processing
  4. Intergovernmental Review
  5. Funding Restrictions
  6. Other Submission Requirements

Section V. Application Review Information
  1. Criteria
  2. Review and Selection Process
    A. Additional Review Criteria
    B. Additional Review Considerations
    C. Sharing Research Data
    D. Sharing Research Resources
  3. Anticipated Announcement and Award Dates

Section VI. Award Administration Information
  1. Award Notices
  2. Administrative and National Policy Requirements
    A. Cooperative Agreement Terms and Conditions of Award
      1. Principal Investigator Rights and Responsibilities
      2. NIH Responsibilities
      3. Collaborative Responsibilities
      4. Arbitration Process
  3. Reporting

Section VII. Agency Contact(s)
  1. Scientific/Research Contact(s)
  2. Peer Review Contact(s)
  3. Financial/ Grants Management Contact(s)

Section VIII. Other Information - Required Federal Citations

Part II - Full Text of Announcement


Section I. Funding Opportunity Description


1. Research Objectives

The purpose of this letter RFA is to solicit competitive supplements from the NCI Community Network Program (CNP) awardees for pilot projects in community based participatory research to reduce health disparities as part of the Community Network Program RFA-CA-05-012 requirement.

Goal and objectives of the CNP Pilot Projects

Phase II of the CNP is the development and implementation of community-based participatory research and training programs to reduce cancer health disparities.   The development of pilot projects is a part of the training program. The previous RFA, CA-05-012, entitled “Community Networks To Reduce Cancer Health Disparities,” included the following statements:

“II.2. Develop pilot research projects.  As part of the CNP research efforts, the Community Networks will develop and implement collaborative developmental pilot research projects involving community-based participatory research in cancer health disparities.  Pilot research projects should address the spectrum of research on cancer health disparities from needs assessments to intervention research to policy assessments.  A principal objective of this research is the development of efficacious community-based participatory interventions to reduce cancer health disparities that can be used nationwide.”

The goals of the CNP pilot project studies are to involve: 1) partnerships of community-based and research organizations in community-based participatory research to reduce disparities; 2) provide preliminary data and results for future research projects; and 3) promote the research experience for researchers involved in minority and underserved populations.  Upon transition to Phase II, each CNP can submit pilot project applications.

The pilot projects are new activities.  The pilot projects should expand the scope of the existing grant and will require additional personnel, equipment, and/or other resources, but the specific aims must remain within the scope of the original RFA, CA-05-012.  A competitive supplement application must be submitted and peer reviewed to obtain funds for pilot projects. 

See Section VIII, Other Information - Required Federal Citations for policies related to this announcement.

Section II. Award Information


1. Mechanism(s) of Support

This funding opportunity will use the NIH competitive supplement to an existing CNP cooperative agreement grant. As an applicant, you will be solely responsible for planning, directing, executing, and reporting the proposed project.

This funding opportunity uses the just-in-time budget concepts. It also uses the non-modular budget format described in the PHS 398 application instructions (see http://grants.nih.gov/grants/funding/phs398/phs398.html).  A detailed categorical budget for the "Initial Budget Period" and the "Entire Proposed Period of Support" is to be submitted with the application.

The NIH U01 is a cooperative agreement award mechanism. In the cooperative agreement mechanism, the PI retains the primary responsibility and dominant role for planning, directing, and executing the proposed project, with NIH staff being substantially involved as a partner with the PI, as described under the Section VI. 2. Administrative Requirements, "Cooperative Agreement Terms and Conditions of Award."  However, these competing supplements are to be performed by the PIs and their staff with no assistance from NCI, unless stated in the application.

2. Funds Available

The NCI intends to commit approximately $2,000,000 dollars in FY 2006 to fund up to 27 competitive supplements in response to this RFA.  An applicant may request a project period of up to 1 year and a budget for direct costs of no more than $49,999 dollars per year.  The number of awards paid from set-aside funds will depend on the overall scientific merit of the applications received.

Although the financial plans for the NCI provide support for this program, awards pursuant to this announcement are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.

Facilities and administrative (F&A) costs requested by consortium participants are not included in the direct cost limitation, see NOT-OD-05-004.

Section III. Eligibility Information


1. Eligible Applicants

1.A. Eligible Institutions

You may submit (an) application(s) if your organization has any of the following characteristics:

Foreign institutions are not eligible to apply.

Eligible institutions or organizations are the current CNP awardees (institutions/organizations) that have approval to transition their CNP to Phase II.

In addition, you must have an active CNP award with a minimum of 2 additional years on the project period.

1.B. Eligible Individuals

Eligible Principal Investigators (PIs) are the current CNP awardees (principal investigators) that have approval to transition their CNP to Phase II.  Co-Investigators, who may conduct pilot projects, are “new” investigators, (see http://grants.nih.gov/grants/guide/notice-files/not97-231.html for the definition of new investigator) and include any individual with the skills, knowledge and resources necessary to carry out the proposed research are invited to work with the PI to develop an application for support.  Individuals from racial/ethnic minorities and underserved population as well as individuals with disabilities are always encouraged to apply for NIH programs.

2. Cost Sharing or Matching
Not applicable.

3. Other-Special Eligibility Criteria

The institution must be the current CNP cooperative agreement (U01) awardee and the PI must be the current PI on the CNP U01 award.

Competitive supplements are available to these NCI grantees to conduct 1-year pilot projects, a Phase II.2 Objective of the Community Network Program RFA-CA-05-012.   

The pilot projects should expand the scope of the existing grant, but the specific aims must remain within the scope of the original RFA, CA-05-012.

The pilot projects are to be conducted and performed by a Co-Investigator, who is a “new” investigator, (see  http://grants.nih.gov/grants/guide/notice-files/not97-231.html for the definition of new investigator) and is not the PI of the CNP award.  The Co-Investigator does not have to be a member of the CNP Institution.  The Co-Investigator may conduct the pilot project as a subcontract from the CNP Institution.  The Co-Investigator may be any individual with the skills, knowledge, and resources necessary to carry out the proposed research.  Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs.     

Per the instructions presented below, a CNP awardee (PI) must be approved to transition his/her CNP to Phase II in order to be eligible to apply for competitive supplements.

Transition to Phase II Requirements

To proceed from Phase I to Phase II, a CNP awardee (PI) should submit a request for approval to transition his/her CNP to Phase II.  The document should address the following factors.  The awardee must have its organizational infrastructure in place and have established a formal partnership with at least one community experiencing disparities—and with at least one primary or secondary prevention facility.  The awardee must also have established a Partnership with at least one cancer research organization and/or University to facilitate recruitment and training of researchers in Cancer health disparities, if the applicant is not one of these groups.  In addition, the awardee needs to have performed at least one cancer education activity to increase community member participation in a primary and/or secondary prevention facility, providing a description of the activity.  A detailed plan for implementation of Phase II should be included.  In addition, documentation is needed that the IRB has reviewed the parent grant.  NCI Program Directors will review the transition documents and approve for the transition for each CNP.  The due date for the transition document is 4 weeks before the due date for the applications, which in this case is March 27, 2006.  The transition document should be sent to the Program Director of the CNP award.  Once approved to Phase II, the CNP can submit pilot project applications.

Section IV. Application and Submission Information


1. Address to Request Application Information

The PHS 398 application instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398.  For further assistance, contact Grants Info, Telephone: (301) 435-0714, Email: GrantsInfo@nih.gov.

Telecommunications for the hearing impaired: TTY 301-451-5936.

2. Content and Form of Application Submission

Applications must be prepared using the most current PHS 398 research grant application instructions and forms.  Applications must have a D&B Data Universal Numbering System (DUNS) number as the universal identifier when applying for Federal grants or cooperative agreements.  The D&B number can be obtained by calling (866) 705-5711 or through the web site at http://www.dnb.com/us/.  The D&B number should be entered on line 11 of the face page of the PHS 398 form.

The title and number of this funding opportunity must be typed on line 2 of the face page of the application form and the YES box must be checked.

3. Submission Dates and Times

Applications must be received on or before the receipt date described below (Section IV.3.A).  Submission times N/A.

3.A. Receipt, Review, and Anticipated Start Dates 

Letter of Intent Receipt Date: March 24, 2006
Application Receipt Date(s): April 24, 2006
Peer Review Date: July 2006
Council Review Date: September 2006
Earliest Anticipated Start Date: September 2006

3.A.1. Letter of Intent

Prospective applicants are asked to submit a letter of intent that includes the following information:

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NIH staff to estimate the potential review workload and plan the review.

The letter of intent is to be sent by the date listed at the beginning of this document.

The letter of intent should be sent to:

Kenneth Chu, Ph.D.
Disparities Research Branch
Center to Reduce Cancer Health Disparities
National Cancer Institute
6116 Executive Boulevard, Room 602, MSC 8341
Bethesda, MD 20892-8341 (for U.S. Postal Service express and regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 496-8589
FAX: 301-435-9225
Email: KC10D@NIH.GOV
 
3.B. Sending an Application to the NIH

Applications must be prepared using the research grant applications found in the PHS 398 instructions for preparing a research grant application.  Submit a signed, typewritten original of the application, including the checklist, and three signed photocopies in one package to:

Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (for U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier delivery; non-USPS service)

Personal deliveries of applications are no longer permitted (see http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-040.html).

At the time of submission, two additional copies of the application and all copies of the appendix material must be sent to:

Referral Officer
National Cancer Institute
Division of Extramural Activities
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329 (for U.S. Postal Service Express or regular mail)
Rockville, MD  20852 (for express/courier delivery)
Telephone: (301) 496-3428
FAX: (301) 402-0275
Email:  ncirefof@dea.nci.nih.gov

Using the RFA Label: The RFA label available in the PHS 398 application instructions must be affixed to the bottom of the face page of the application.  Type the RFA number on the label. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review.  In addition, the RFA title and number must be typed on line 2 of the face page of the application form and the YES box must be marked.  The RFA label is also available at: http://grants.nih.gov/grants/funding/phs398/labels.pdf.

3.C. Application Processing

Applications must be received on or before the application receipt date(s) described above (Section IV.3.A.).  If an application is received after that date, it will be returned to the applicant without review.  Upon receipt, applications will be evaluated for completeness by the CSR and for responsiveness by the NCI Incomplete and non-responsive applications will not be reviewed.  If the application is not responsive to the RFA, the application will be returned to the applicant.  The NIH will not accept any application in response to this funding opportunity that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application.  However, when a previously unfunded application, originally submitted as an investigator-initiated application, is to be submitted in response to a funding opportunity, it is to be prepared as a NEW application.  That is, the application for the funding opportunity must not include an Introduction describing the changes and improvements made, and the text must not be marked to indicate the changes from the previous unfunded version of the application.

Although there is no immediate acknowledgement of the receipt of an application, applicants are generally notified of the review and funding assignment within 8 weeks.

4. Intergovernmental Review

This initiative is not subject to intergovernmental review.

5. Funding Restrictions


All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.  The Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.
 
No pre-award costs are allowable.

6. Other Submission Requirements

APPLICATION DETAILS

The pilot project application will follow the standard format of the R01 (PHS 398) application except the Research Plan will be limited to 15 pages instead of the usual 25 pages.

Special Instructions for Recommended Format:
Form 398 Face page:
Box 3a - List name of PI for existing CNP cooperative agreement.
Applicant organization is the CNP Grantee.
Box 15 - CNP PI signs.
Box 16 - Business office of CNP Grantee signs.

Key Personnel
CNP PI should be listed first and identified as the PI, last name first.  PI of pilot project should be listed next and identified as Co-Investigator.  Other key personnel and consultants for the competitive supplement should then be listed.

Budget Instructions
A maximum of $49,999 direct costs may be requested.  Follow the instructions for non-modular budget research grant applications.  A detailed categorical budget is to be submitted and the budget requested should reflect the total direct costs only of items for which additional funds are requested.  If the initial budget period of the supplemental application is less than 12 months, prorate the personnel costs and other appropriate items of the detailed budget.

RESEARCH PLAN (15 page maximum, instead of normal 25 pages)
A. Specific Aims – Specific aims should include the goals and objectives of the pilot project.
B. Background and Significance – In this section, the applicant should provide a description of the cancer health disparities of the communities to be addressed and its significance.
C. Feasibility/Preliminary Studies/Progress Report– For this program, emphasis should be placed on demonstrating the techniques/approaches are feasible rather than on preliminary results.
D. Research Design and Methods - Describe your proposed CNP in detail.
Discuss how the aims will be achieved, such as a discussion of how the disparities in the community are to be reduced, the interventions to be used, the metrics that will be used to measure reductions in disparities, the partnerships and collaborations proposed, etc.
E.  Role and Qualifications of the Mentor – Describe how the mentor will help the “new” investigator and describe the mentor’s qualifications as they relate to the project.

Suggested Outline for Research Plan: Length: (15 pages, maximum)
A.  Specific Aims-1 page or less
B.  Background/Significance - 1 page or less
C. Feasibility/Preliminary Studies/Progress Report – 1-2 pages or less
D.  Research Design and Methods –  up to 11 pages
E.  Role and Qualifications of the Mentor – 1-2 pages or less

Human Subjects, Vertebrate Animals, Literature Cited  and Appendices do not count in the 15-page Research Plan.  

The Co-Investigator, who is to perform the pilot project, must be a “new” investigator (see  http://grants.nih.gov/grants/guide/notice-files/not97-231.html for the definition of new investigator) and not the PI of the CNP.  PI of pilot project may be a Co-Investigator of the CNP.  The Co-Investigator does not have to be from the Institution that has been awarded the CNP grant.  The Co-Investigator can be subcontracted from the awarded Institution.  Researchers from minority and underserved populations are encouraged.  A letter of commitment signed by the PI and Co-Investigator should be included in the appendix. 

Each eligible CNP may submit up to four pilot project applications.  Submit each application on a separate PHS 398 form and in a separate package.  Each CNP can have up to four pilot project applications funded per year.  

Plan for Sharing Research Data
Not applicable
 
Sharing Research Resources

NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (see the NIH Grants Policy Statement at http://grants.nih.gov/grants/policy/nihgps_2003/index.htm and at http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part7.htm#_Toc54600131).  Investigators responding to this funding opportunity should include a plan for sharing research resources addressing how unique research resources will be shared or explain why sharing is not possible.

The adequacy of the resources sharing plan and any related data sharing plans will be considered by Program staff of the funding organization when making recommendations about funding applications.  The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report (PHS 2590, http://grants.nih.gov/grants/funding/2590/2590.htm).  See Section VI.3. Reporting.

Section V. Application Review Information


1. Criteria

Only the review criteria described below will be considered in the review process.

The following will be considered in making funding decisions:

2. Review and Selection Process

Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by Division of Extramural Activities of the NCI in accordance with the review criteria stated below.

As part of the initial merit review, all applications will:

The goals of NIH supported research are to advance our understanding of biological systems, to improve the control of disease, and to enhance health.  In their written critiques, reviewers will be asked to comment on each of the following criteria in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals.  Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application.  Note that an application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score.  For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward.

Significance: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced? What will be the effect of these studies on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Approach: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? (For this program, emphasis should be placed on demonstrating the techniques/approaches are feasible than on preliminary results.)  The pilot projects should deal with community-based projects that can reduce disparities and not basic science/laboratory projects.

Innovation: Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, and/or technologies for this area?

Investigators: Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the PI and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)? (For this program, emphasis should be placed on their training and their research potential including their mentor than on their track record and number of publications.)

Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support? (For this program, there should be some evidence of institutional commitment in terms of space and time to perform research.)

2.A. Additional Review Criteria

In addition to the above criteria, the following items will continue to be considered in the determination of scientific merit and the priority score:

Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed (see the Research Plan, Section E on Human Subjects in the PHS Form 398).

Inclusion of Women, Minorities and Children in Research: The adequacy of plans to include subjects from both genders, all racial and ethnic groups (and subgroups), and children as appropriate for the scientific goals of the research will be assessed. Plans for the recruitment and retention of subjects will also be evaluated (see the Research Plan, Section E on Human Subjects in the PHS Form 398).

Care and Use of Vertebrate Animals in Research: If vertebrate animals are to be used in the project, the five items described under Section F of the PHS Form 398 research grant application instructions will be assessed.

Biohazards: If materials or procedures are proposed that are potentially hazardous to research personnel and/or the environment, determine if the proposed protection is adequate.

2.B. Additional Review Considerations

Budget: The reasonableness of the proposed budget and the requested period of support in relation to the proposed research. The priority score should not be affected by the evaluation of the budget.

2.C. Sharing Research Data
Not applicable

2.D. Sharing Research Resources

NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (see the NIH Grants Policy Statement at http://grants.nih.gov/grants/policy/nihgps/part_ii_5.htm#availofrr and at http://www.ott.nih.gov/policy/rt_guide_final.html). Investigators responding to this funding opportunity should include a sharing research resources plan addressing how unique research resources will be shared or explain why sharing is not possible.

The adequacy of the resources sharing plan will be considered by Program staff of the funding organization when making recommendations about funding applications. Program staff may negotiate modifications of the data and resource sharing plans with the awardee before recommending funding of an application. The final version of the data and resource sharing plans negotiated by both will become a condition of the award of the grant. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report (PHS 2590). See Section VI.3. Reporting.

3. Anticipated Announcement and Award Dates
Not applicable

 Section VI. Award Administration Information


1. Award Notices

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant. For details, applicants may refer to the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part4.htm).

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the grants management officer is the authorizing document. Once all administrative and programmatic issues have been resolved, the NoA will be generated via email notification from the awarding component to the grantee business official (designated in item 12 on the Application Face Page). If a grantee is not email enabled, a hard copy of the NoA will be mailed to the business official.

Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See also Section IV.5. Funding Restrictions.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm) and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part9.htm).

The following Terms and Conditions will be incorporated into the award statement and will be provided to the PI as well as to the appropriate institutional official, at the time of award.

2.A. Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, DHHS grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other DHHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be competitive supplements to cooperative agreement from RFA-CA-05-012.  These supplements are to be performed by the PIs and their staff with no assistance from NCI, unless stated in the application.

2.A.1. Principal Investigator (PI) Rights and Responsibilities

The PI of the competitive supplement will have primary responsibilities as follows:

a. Awardees have primary authority and responsibility to define objectives and approaches and to plan, conduct, analyze, and publish results, interpretations, and conclusions of their projects.  Awardees must establish and maintain a Project Steering Committee.  The role and responsibilities of the Steering Committee are described below under “Collaborative Responsibilities.”

b. Awardees must manage the performance of the pilot project.

c. Awardees will retain custody of and have primary rights to data collected under these awards, subject to Government rights of access consistent with current U.S. Department of Health and Human Services (DHHS) policies, such as Health Insurance Portability and Accountability Act (HIPAA) regulations, Public Health Service (PHS) policies, and National Institutes of Health (NIH) policies.

The CNP Steering Committee and the Community Advisory Group may provide advice on pilot projects. Any disagreement that may arise on scientific/programmatic matters (within the scope of the award) between award recipients and the NCI may be brought to arbitration. (See “Arbitration,” below.)

d. Awardees must provide annual progress reports of the pilot projects and additional information, as requested by the NCI Program Coordinator. Upon completion of the pilot project, awardee will submit a paper describing the study with abstract, introduction, methods, results, discussion and references, to be completed by the PI of the pilot project.  This paper is due with the progress report for the parent grant.

2.A.2. NIH Responsibilities

NCI Staff Responsibilities –

The NCI Program Coordinator (and other NCI staff) will have substantial scientific/programmatic involvement during the conduct of the CNP through technical assistance, advice, and coordination above and beyond normal program stewardship for grants, as described below.  The NCI Program Coordinator shall:

a. Serve as a member of the Steering Committee;

b. Assist awardees with planning and establishing priorities and approve awardees’ plans prior to implementation of Phase activities;

c. Determine whether an awardee-planned community activity or pilot project is consistent with NCI guidelines;

d. Coordinate activities with other Federal agencies (e.g., the Centers for Disease Control and Prevention (CDC), Centers for Medicare & Medicaid Services (CMS), and DHHS Office of Minority Health [OMH]) and

broker interactions between NCI and awardees, as necessary, to provide technical assistance and guidance in specialty areas, as well as arrange short-term training assignments for minority researchers; and 

e. Convene special meetings and ad hoc groups to address NCI priority issues.

f. The NCI staff will not be involved in the pilot projects of the competitive supplements, unless indicated by the application.

An NCI Program Director will be responsible for normal program stewardship of this award, including monitoring of progress and other required reports. The Program Director may identify other NCI staff to provide technical assistance in specific areas as needed. The Program Director may also serve as the Program Coordinator.

NCI reserves the right to terminate or curtail the program (or an individual award) in the event of substantial shortfall in the performance of requirements for any single Phase or key activity of the program.

2.A.3. Collaborative Responsibilities

Awardees will collaborate with the NCI Program Coordinator to establish and maintain for their projects a Steering Committee whose role is to function as a governing body.  The Steering Committee will appropriately comprise scientists and community leaders and/or facilitators and will set policy, provide overall guidance and direction, and provide support for project-sponsored activities.  Membership will include the Project PI, NCI Program Coordinator, Regional PIs, and others with expertise in relevant scientific or other cancer-related or disparity-related disciplines. Responsibilities of the Steering Committee include: reviewing and ensuring scientific soundness of project plans; guiding development and implementation of population-specific cancer control and prevention activities; approving joint and pilot research project plans and applications; prioritizing project needs; promoting collaborations; and facilitating interactions among the NCI, partners, and community populations.  The PI will serve as chairperson of the Steering Committee and be responsible for selecting other members.  Decisions and recommendations of the Steering Committee will be binding and take precedence over those of regional advisory committees.

The pilot projects are to be performed by the PI and staff of the pilot project applications. NCI will not become involved in the pilot project, unless indicated by the application.

2.A.4. Arbitration Process

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to arbitration.  An Arbitration Panel composed of three members will be convened.  It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee.  This special arbitration procedure in no way affects the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulations 42 CFR Part 50, Subpart D and HHS regulations 45 CFR Part 16.

3. Reporting

Awardees will be required to submit the PHS Non-Competing Grant Progress Report, Form 2590, annually (http://grants.nih.gov/grants/funding/2590/2590.htm) and financial statements as required in the NIH Grants Policy Statement.

Section VII. Agency Contacts


We encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research, peer review, and financial or grants management issues:

1. Scientific/Research Contacts:

Kenneth Chu, Ph.D.
Disparities Research Branch
Center to Reduce Cancer Health Disparities
National Cancer Institute
6116 Executive Blvd, Room 602, MSC 8341
Bethesda, MD 20892-8341 (for U.S. Postal Service express and regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 496-8589
FAX: 301-435-9225
Email: KC10D@NIH.GOV

2. Peer Review Contacts:

Referral Officer
National Cancer Institute
Division of Extramural Activities
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 496-3428
FAX: (301) 402-0275          
Email: ncirefof@dea.nci.nih.gov

3. Financial or Grants Management Contacts:

Crystal Wolfrey
Grants Administration Branch
National Cancer Institute
6120 Executive Boulevard, Room 243, MSC 7150
Bethesda, MD 20892-7150 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 496-8634
FAX: (301) 496-8601
Email: Crystal.Wolfrey@nih.gov

Section VIII. Other Information


Required Federal Citations

Use of Animals in Research:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.

Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).

Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (Phase I); efficacy studies (Phase II); and efficacy, effectiveness, and comparative trials (Phase III). Monitoring should be commensurate with risk. The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants (NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, http://grants.nih.gov/grants/guide/notice-files/not98-084.html).

Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (http://grants.nih.gov/grants/policy/data_sharing).

Investigators should seek guidance from their institutions on issues related to institutional policies and local institutional review board (IRB) rules, as well as local, State, and Federal laws and regulations, including the Privacy Rule. Reviewers will consider the data sharing plan but will not factor the plan into the determination of the scientific merit or the priority score.

Access to Research Data through the Freedom of Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are: (1) first produced in a project that is supported in whole or in part with Federal funds; and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at  http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this funding opportunity in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.

Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see http://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time, the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh-Dole Act (see the NIH Grants Policy Statement at http://grants.nih.gov/grants/policy/nihgps_2003/index.htm). All investigators submitting an NIH application or contract proposal, beginning with the October 1, 2004, receipt date, are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. This will permit other researchers to benefit from the resources developed with public funding. The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.

Inclusion of Women And Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the new PHS Form 398; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.

Inclusion of Children as Participants in Clinical Research:
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them.

All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (http://grants.nih.gov/grants/funding/children/children.htm).

Required Education on the Protection of Human Subject Participants:
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel. The policy is available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.

Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov). It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s) to be used in the proposed research. Applications that do not provide this information will be returned without review.

NIH Public Access Policy:
NIH-funded investigators are requested to submit to the NIH manuscript submission (NIHMS) system (http://www.nihms.nih.gov) at PubMed Central (PMC) an electronic version of the author's final manuscript upon acceptance for publication, resulting from research supported in whole or in part with direct costs from NIH. The author's final manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process.

NIH is requesting that authors submit manuscripts resulting from: 1) currently funded NIH research projects or 2) previously supported NIH research projects if they are accepted for publication on or after May 2, 2005. The NIH Public Access Policy applies to all research grant and career development award mechanisms, cooperative agreements, contracts, Institutional and Individual Ruth L. Kirschstein National Research Service Awards, as well as NIH intramural research studies. The Policy applies to peer-reviewed, original research publications that have been supported in whole or in part with direct costs from NIH, but it does not apply to book chapters, editorials, reviews, or conference proceedings. Publications resulting from non-NIH-supported research projects should not be submitted.

For more information about the Policy or the submission process, please visit the NIH Public Access Policy Web site at http://publicaccess.nih.gov/ and view the Policy or other Resources and Tools including the Authors' Manual (http://publicaccess.nih.gov/publicaccess_Manual.htm).

Standards for Privacy of Individually Identifiable Health Information:
The Department of Health and Human Services (DHHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information," the "Privacy Rule," on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR).

Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.

URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site.

Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This PA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.

Authority and Regulations: 
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.

The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.

Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas. The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt. Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged. The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50 percent of their time (at least 20 hours per week based on a 40-hour week) for 2 years to the research. For further information, please see http://www.lrp.nih.gov.


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.